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Abstract
Posthaemorrhagic hydrocephalus (PHH) is a major problem for premature infants, generally requiring
lifelong care. It results from small blood clots inducing scarring within CSF channels impeding CSF
circulation. Transforming growth factor – beta is released into CSF and cytokines stimulate deposition of
extracellular matrix proteins which potentially obstruct CSF pathways. Prolonged raised pressures and
free radical damage incur poor neurodevelopmental outcomes. The most common treatment involves
permanent ventricular shunting with all its risks and consequences.
This is a review of the current evidence for the treatment and prevention of PHH and shunt dependency.
The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library) and PubMed
(from 1966 to August 2008) were searched. Trials using random or quasi-random patient allocation for
any intervention were considered in infants less than 12 months old with PHH. Thirteen trials were
identified although speculative interventions were also evaluated.
The literature confirms that lumbar punctures, diuretic drugs and intraventricular fibrinolytic therapy can
have significant adverse effects and fail to prevent shunt dependence, death or disability. There is no
evidence that postnatal phenobarbital administration prevents intraventricular haemorrhage (IVH).
Subcutaneous reservoirs and external drains have not been tested in randomized controlled trials, but can
be useful as a temporising measure. Drainage, irrigation and fibrinolytic therapy as a way of removing blood
to inhibit progressive deposition of matrix proteins, permanent hydrocephalus and shunt dependency, are
invasive and experimental. Studies of ventriculo-subgaleal shunts show potential as a temporary method
of CSF diversion, but have high infection rates.
At present no clinical intervention has been shown to reduce shunt surgery in these infants. A ventricular
shunt is not advisable in the early phase after PHH. Evidence exists that pre-delivery corticosteroid therapy
reduces mortality and IVH and there may be trends towards reduced disability in the short term. There
is also evidence that postnatal indomethacin reduces IVH but with no effect on mortality or disability.
Overall, there is still no definitive algorithm for the treatment of PHH or prevention of shunt dependence.
New therapeutic approaches in neonatal care, including those aimed at pre-empting PHH, offer the best
hope of improving neurodevelopmental outcomes.
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Introduction
Intraventricular haemorrhage (IVH) remains a serious
complication of premature birth. Despite many treatment
options, there is still no consensus on the management of
post-haemorrhagic hydrocephalus (PHH) in the very low
birth weight (VLBW) baby. Although improvements in
obstetric and perinatal care have decreased the incidence
and severity of IVH in low-weight preterm infants from
40–50% in the 1980s, to 20–25% in the 1990s [1,2], the
problem still remains important as the survival rate of
very immature newborns increases [3]. Moreover, there is
a direct correlation between increasing prematurity and
severity of the IVH. A 1998–2000 study reported IVH
grade III in 32% of premature infants born at 24–26
weeks' gestation and IVH grade IV in 19% of this group,
whereas in infants born at 31–32 weeks gestation the inci-
dences of IVH grades III and IV were 11% and 5% respec-
tively [4]. Additionally, the percentage of patients
developing hydrocephalus secondary to this haemorrhage
varies greatly. In the last 20 years different medical and
surgical treatments have been put forward to prevent both
the occurrence of haemorrhage and the development of
hydrocephalus. In this study we reviewed the literature on
the different treatments used to control and treat PHH.
Background
With improvement in neonatal intensive care, more chil-
dren with PHH are surviving. Murphy et al. provided evi-
dence that posthaemorrhagic ventricular dilation in the
1990s had a more aggressive course than previously [1].
This is presumably due to the increasing survival of
infants of progressively lower birth weight and gestation
followed by improvements in neonatal care, such as the
widespread use of antenatal steroids and surfactants.
However the less well-developed brain in these very pre-
mature neonates may also be more readily damaged by
haemorrhage or increased intracranial pressure (ICP).
Haemorrhage into the ventricles of the brain is amongst
the most serious complications of preterm birth despite
improved survival rates. Large IVH has a high risk for neu-
rological disability, and more than 50% of these children
go on to develop progressive ventricular dilation [3].
Extreme prematurity associated with PHH results in high
morbidity and considerable mortality [1,5]. The hydro-
cephalus is usually ascribed to fibrosing arachnoiditis,
meningeal fibrosis and subependymal gliosis, which
impairs the flow and reabsorption of cerebrospinal fluid
(CSF). Initially, multiple blood clots may obstruct the
ventricular system or CSF reabsorption channels, such as
from thrombus formation within the cisterna magna [6].
This leads to a chronic arachnoiditis of the basal cisterns,
involving deposition of extracellular matrix proteins in
the foramina of the fourth ventricle and in the subarach-
noid space [7,8].
Recent experimental studies have suggested that acute
parenchymal compression and ischaemic damage, with
increased parenchymal and perivascular deposition of
extracellular matrix proteins, are the important contribu-
tors to the development of arachnoiditis and hydroceph-
alus [8]. Transforming growth factor beta (TGF-beta) is a
cytokine that up regulates the production by fibroblasts of
extracellular matrix proteins. TGF-beta is involved in the
initiation of wound healing and fibrosis [9]. TGF-beta ele-
vates the expression of genes encoding fibronectin, vari-
ous types of collagen [10,11], and other extracellular
matrix components [12]. There is evidence that TGF-beta
may be a mediator of the pathological process [13].
Previous studies suggest that these changes take place over
weeks. Heep et al. in 2004 confirmed that TGF-beta CSF
concentrations are in fact not elevated in the acute phase
of fibroproliferative reactions in patients with PHH [14].
However, this study demonstrated that vascular endothe-
lial growth factor (VEGF) is highly expressed in the CSF of
neonates with PHH and may serve as an indicator of brain
injury from progressive ventricular dilation. Further stud-
ies confirmed that intraventricular blood and ventricular
expansion may have adverse effects on the immature
periventricular white matter by a variety of other mecha-
nisms, including physical distortion, raised ICP [15], free
radical generation facilitated by liberated iron [16], and
inflammation [17]. The haemorrhage can be isolated or it
can rupture through the ependymal lining into the ven-
tricular system. If the haemorrhage is large it may extend
into the parenchymal tissue adjacent to the germinal
matrix. The majority of haemorrhages occur within 72
hours of birth.
Despite all the difficulties in isolating a pathogenetic
mechanism, there is little doubt that IVH is associated
with damage to periventricular white matter and this
damage is exacerbated by the development of hydroceph-
alus. Combinations of pressure, distortion, ischaemia,
inflammation, and free radical-mediated injury are the
main contributors. Importantly, damage to white matter
accounts for the high frequency of cerebral palsy and poor
neurodevelopmental outcome, in this group of infants.
The aim of much of past and ongoing research is to iden-
tify mechanisms and mediators of hydrocephalus and
white matter damage, which may enable new treatments
that avoid permanent hydrocephalus, with its potential
neurological sequelae, and avoid shunt dependence.
Treatment is more difficult than with other types of
hydrocephalus. The large amount of blood and protein in
the CSF, combined with the small size and instability of
the patient, makes early ventriculoperitoneal (VP) shunt
operations unrewarding, due to the high incidence of
blockage and infection [18]. There is a considerable com-Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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plication rate throughout later life from such surgery, and
the child is generally permanently dependent on the
shunt system [19]. Several studies act as testament to this
difficulty. Pikus et al. [20] evaluated 52 patients with
Grade IV IVH and progressive hydrocephalus treated
between 1977 and 1987. These patients averaged 6.9
shunt revisions over 18 years. Mortality was 60%; 78% of
survivors had intellectual function more than 2 standard
deviations below the mean for age and all survivors had
some form of spasticity. Boynton et al. [18] reported out-
comes for 50 preterm infants with PHH, 92% with Grade
III or Grade IV haemorrhages. Mortality was 7% with a
median shunt revision rate of 4 per patient and shunt
infection rate of 19% per procedure, with a failure rate of
92% for those treated in the first 3 weeks of life. Neurode-
velopmental outcomes included strabismus (40%),
blindness (28%) and hearing loss (24%). Seizures
occurred in 38% and most required long-term anticonvul-
sants. Additionally, significant limitations in motor func-
tion occurred in 49%. More recently, a large cohort study
by Adams-Chapman et al. [21] into 6161 extremely low
birth weight children, confirmed that those with severe
IVH that require shunt insertion are at greater risk for
adverse neurodevelopmental and growth outcomes at 18
to 22 months, compared with children with and without
severe IVH and with no shunt. These poor outcomes rein-
force the need for more alternative treatments, though
they are not necessarily caused by the shunt, perhaps
being due to the underlying processes leading to shunt
dependence.
Anatomy and pathophysiology
Germinal matrix haemorrhage (GMH) and IVH are the
most common and most important events that cause neu-
rological injuries in preterm neonates. The homeostatic
compensatory capacity of a premature infant is limited.
Fluctuations in cerebral blood pressure and flow can rup-
ture the primitive germinal matrix vessels or lead to infarc-
tion of the metabolically active germinal matrix. The
damage can extend into the periventricular white matter,
resulting in significant neurological sequelae, including
cerebral palsy, mental retardation, and seizures. As has
been mentioned, injury to the germinal matrix results in
substantial mortality and morbidity rates.
The germinal matrix is located in the subependyma of the
ventricular walls. At 8–28 weeks' gestation, the germinal
matrix initially produces neurons and subsequently glial
cells, which migrate to populate the cerebral cortex. Invo-
lution of the germinal matrix toward the caudothalamic
groove begins late in the second trimester and is nearly
complete by 32 weeks' gestation [22]. The germinal matrix
is metabolically active with a rich supply of blood via thin,
fragile capillary networks, supplied by branches of the
anterior cerebral artery. The arterioles flow from the recur-
rent artery of Heubner at the level of the foramen of
Monro and the terminal branches of the lateral striate
arteries, which are located more superiorly. Venous blood
flows through the terminal vein, which drains via the
internal cerebral vein into the vein of Galen [23].
The neuropathology of GMH/IVH is characterised by
bleeding into the subependymal germinal matrix, with or
without subsequent rupture into the lateral ventricle. The
pathogenesis of GMH is multifactorial. The influences can
be divided into intravascular, vascular, and extravascular
factors. The autoregulation of blood flow in response to
changes in blood pressure in the germinal matrix circula-
tion is underdeveloped in premature infants, and the thin
microvasculature is susceptible to rupture. The immature
mesenchymal and glial supportive tissues also influence
the extent of GMH. Large fluctuations in blood flow and
blood pressure can lead to injury to the germinal matrix
vessels and subsequent haemorrhage [24]. Moreover, the
highly metabolically active germinal matrix is particularly
vulnerable to hypotension and hypoperfusion, and this
can lead to focal or diffuse infarction. Consequently,
haemorrhage can occur in the infarcted regions after
reperfusion. Haemorrhage from any cause can be con-
fined to the subependymal layer, can extend into the ven-
tricles or arise from the brain parenchyma [23]. The
aetiology is probably due to obstruction of venous drain-
age by blood clot in the germinal matrix [25]. Thus, inter-
ventions aimed at prevention or treatment of IVH might
be aimed at any of the above mechanisms. Sequelae of
GMH/IVH include germinal matrix destruction, periven-
tricular haemorrhagic infarction with subsequent enceph-
alomalacia, and PHH. The major risk factors for GMH
include a young gestational age, low birth weight, acute
amnionitis, and not receiving antenatal steroids for at
least 48 hours. Other neonatal risk factors include the use
of general anaesthesia for caesarean delivery, Apgar scores
that are less than 4 in the first minute or are less than 8 by
5 minutes, respiratory distress, patent ductus arteriosus,
anaemia and arterial catheterisation [26-28].
More evidence for the deleterious effects of PHH comes
from studies by near-infrared spectroscopy (NIRS). NIRS
permits continuous measurement of changes in the cere-
bral concentration of oxygenated and deoxygenated hae-
moglobin and oxidized cytochrome oxidase at the
bedside of infants. A recent study showed that cerebral
perfusion, cerebral blood volume, and oxidative metabo-
lism are all compromised in infantile PHH to the degree
whereby removal of any volume of CSF led to a significant
improvement in these parameters [29]. This further dem-
onstrates how harmful the resultant PHH can be to the
cerebral haemodynamics of infants.Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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Diagnosis and grading of IVH and PHH
Ultrasonography (US) is the primary imaging modality
for the screening and diagnosis of GMH/IVH, and com-
puted tomography (CT) scanning and magnetic reso-
nance imaging (MRI) are used as supplementary tools
[30]. Figure 1 shows MRI sequences of a VLBW infant nine
days after birth with hydrocephalus and intraventricular
and caudo-thalamic groove haemorrhages. Cranial ultra-
sound (US) can be carried out at the cot side and does not
expose the infant to ionizing radiation [31]. This enables
whole populations of infants to be safely examined. The
classification of IVH by Papile in 1978 was originally
developed for computed tomography (CT) scanning, but
has been adopted by ultrasonographers [32]. Figures 2A
and 2B demonstrate coronal and sagittal US images in a
normal infant, and Figures 3A–C show views of grade III
IVH and subsequent hydrocephalus six weeks later.
Four grades identified for IVH are
Grade I or mild haemorrhage is confined to the subepend-
ymal germinal matrix with no blood clot in the ventricular
lumen. Figure 4A shows a coronal US image with grade I
IVH highlighted in the left caudothalamic groove.
Grade II or moderate subependymal haemorrhage
involves minimal filling (10–40%) of the lateral ventricles
with little or no ventricular enlargement. Figure 4B is a
coronal US image pointing out grade II IVH in the right
caudothalamic groove.
Grade III or severe subependymal haemorrhage is associ-
ated with substantial filling of the lateral ventricles (>
50%) with significant ventricular enlargement (Figure 3).
Grade IV or periventricular haemorrhagic infarction is
IVH plus intraparenchymal venous haemorrhage. Figure
4C is a coronal US highlighting a right grade IV large IVH
with hydrocephalus and extension into periventicular
white matter.
Although US diagnosis of GMH is not perfect, with sensi-
tivity of 61% and specificity 78%, the diagnosis of IVH
shows high sensitivity (91%) and specificity (81%) as
does identification of parenchymal haemorrhage (sensi-
tivity 82% and specificity 97%) [33].
Literature search
Literature searches were performed using PubMed and the
Cochrane Central Register of Controlled Trials (CEN-
TRAL, The Cochrane Library Issue 2, 2008). Randomised
or quasi-randomised controlled trials were considered as
primary (level 1) evidence for treatment (see additional
file 1). Other small-scale studies were considered to affirm
potential and understudied therapies. All types of inter-
vention were considered in infants of less than 12 months
of age with hydrocephalus following IVH.
Shunt treatment and complications
At the present time, the best definitive treatment for
hydrocephalus in preterm infants is still the VP shunt. The
most suitable time for surgery is when the newborn infant
exceeds 1500 g [34] and the CSF has a protein content
below 200 mg/dL [35]. However, alongside poor long
term outcomes, there are many problems with this
method. Firstly, the surgical treatment is still complicated
by high revision rates [36,37]. Secondly, the prematurity
of the patients and their relatively incompetent immune
system favours shunt infections. The infection rate varies
across the studies and is usually between 5–15%. 3. Also
increased CSF protein levels predispose to shunt obstruc-
tions which are the most common cause of shunt failure
in these children [18,36-38], with the rate of shunt failure
reportedly being higher in ventriculoatrial shunts [38].
Furthermore, physiologically very low ICP levels in pre-
mature infants necessitate special shunt systems, which
bring more potential problems. For low birth weight
infants, low pressure valves or even valveless shunts are
recommended [39]. Problematically, low pressure valves
may have to be converted later to higher pressure valves,
or include systems with a component to prevent over
drainage when upright as the child starts to sit and stand.
Therefore, there is a high rate of shunt revision even in the
absence of blockage, unless externally programmable
valves are used. In addition, shunt over drainage with col-
lapsed ventricles and eventual subdural fluid collections
and/or secondary craniostenosis can occur in children
with low pressure valve systems [37,40]. Some authors,
therefore, advocate shunts with programmable valves as
the first choice although there is in fact limited evidence
as to the superiority of one valve over another in address-
ing these risks, which only underlines the uncertainties in
using these devices [41,42]. There is also controversy
about the setting for the surgery. Some authors advocate
the neonatal intensive care unit (ICU) as the most com-
fortable and safest for premature patients [43]. Finer et al.
[44] demonstrated that the unstable neonate can undergo
surgery in the neonatal ICU with a surgical morbidity and
mortality comparable to that seen in theatre, as transpor-
tation predisposes the critically ill neonate to hypother-
mia, frequently results in dislodgement of intravascular
catheters, and is likely to increase postoperative pain.
However, these studies apply to general procedures with
no specific evidence for relevance to shunt operations.
Therefore, given the high infection rate of shunting pre-
term neonates with PHH, this is an environment probably
best limited to external ventricular drain (EVD) place-
ment, unless evidence of safety emerges [45].Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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MR images of the head of a very low birth weight infant nine days after birth Figure 1
MR images of the head of a very low birth weight infant nine days after birth. A: Sagittal T1-weighted MRI showing 
layering of the intraventricular haemorrhage within the venticles and in the posterior fossa (arrows). B: CISS (Constructive 
Interference in the Steady State) sequence giving heavily T2-weighted high resolution images with excellent fluid contrast dem-
onstrating the dilated ventricular system in white and the dependent haemorrhage (arrows). C: T1-weighted axial MRI scan 
showing layering of the intraventricular haemorrhage (arrows) and a left scalp haematoma (arrowhead). D: T2-weighted axial 
MRI showing layering of the intraventricular haemorrhage (arrows) and a left scalp haematoma (arrowhead). The most striking 
features on these scans are hydrocephalus with intracranial haemorrhage, which is seen layering within the lateral ventricles.Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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Nevertheless, VP shunting is clearly still a treatment with
many problems in preterm infants with PHH, and preven-
tion or alternative therapies are undoubtedly needed.
Medical and minimally invasive treatments
Diuretic therapy
Medical treatment of PHH consists of oral or intravenous
administration of drugs that reduce CSF production.
Acetazolamide and furosemide, which both reduce the
production of CSF, have been suggested as non-invasive
therapies to reduce hydrocephalus and the need for VP
shunting. There are two level 1 trials of acetazolamide
and/or furosemide compared with standard therapy in
infants with IVH or post-haemorrhagic ventricular dilata-
tion (PHVD); one randomized with 16 infants [46] and
the other with 177 infants [47]. Neither study showed a
decreased risk for VP shunt or death with acetazolamide
and furosemide therapy. In the multicentre trial with 177
infants by the International PHVD Drug Trial Group [47]
acetazolamide in doses of 100 mg/kg/day, and furosem-
ide 1 mg/kg/day were administered. None of the measures
of outcome in this study suggested any advantage from
drug treatment. They concluded that substantial future
reductions in the adverse consequences of PHVD were
most likely to come from continuing changes in neonatal
care that contribute to its prevention rather than to its
treatment. In total, 65% of infants receiving the drug treat-
ment died or required shunt insertion and 46% of infants
in the control group died or required shunt insertion. In
the drug treatment group, 79% of infants were impaired
or disabled at 1 year, whereas 53% of those in the control
group were impaired or disabled at 1 year. The CNS infec-
tion levels were similar in both groups. Additionally, this
large trial demonstrated that acetazolamide and furosem-
ide treatment resulted in a borderline increase in the risk
for motor impairment at one year (RR 1.27, 95% CI 1.02
– 1.58; RD 0.16, 95% CI 0.02 – 0.31). However, when the
combined outcomes of death, developmental delay, disa-
bility or impairment at one year were considered there
was no significant increase in risk. Another finding was
that diuretic treatment increased the risk for nephrocalci-
nosis (RR 5.31, 95% CI 1.90 – 14.84; RD 0.19, 95% CI
0.09 – 0.29) and a meta-analysis has confirmed the signif-
icance of this result [48]. Thus the diuretic therapy
increased nephrocalcinosis and biochemical anomalies,
which led to the cessation of treatment. Additionally, the
available evidence supports the assertion that diuretic
therapy increases the risk of motor impairment and disa-
bility [48]. As the results clearly showed a worse outcome
in the drug-treated infants, the data-monitoring commit-
tee prematurely halted the trial.
The rationale for treatment with these drugs is to decrease
the rate of CSF formation, but they have other effects.
There is the potential to cause cerebral vasodilatation and
impairment of autoregulation, leading to enhanced risk of
secondary cerebral injury. Moreover, data from experi-
mental studies suggest that acetazolamide may be toxic to
the developing oligodendrocyte [49]. The adverse effects
seen in these trials, however, are probably best explained
by alterations in cerebral perfusion pressure [47]. There-
fore, available evidence shows that acetazolamide and
furosemide do not reduce the need for VP shunting in
infants with PHH, being neither effective nor safe.
Ultrasound images of the head of a 2 week old normal term  infant scanned with an 8V5 ultrasound probe on an Acuson  Sequoia 512 ultrasound machine (Siemens, Erlanger, Ger- many) Figure 2
Ultrasound images of the head of a 2 week old nor-
mal term infant scanned with an 8V5 ultrasound 
probe on an Acuson Sequoia 512 ultrasound machine 
(Siemens, Erlanger, Germany). A: Sagittal view, arrow 
indicates the caudo-thalamic groove used as a reference 
point. B: Coronal view, again arrow referencing the normal 
caudo-thalamic groove.Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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Fibrinolytic agents
Treatments involving fibrinolytic agents carry a high risk
of triggering new haemorrhages, but in recent years their
use has been taken up again in combination with ven-
tricular drains. The effect of intraventricular streptokinase
was determined on the risk of permanent shunt depend-
Ultrasound images of a 2 day old premature infant born at 28 weeks scanned with a C8-5 ultrasound probe on a Philips iE33  ultrasound machine (Philips Medical Systems, Eindhoven, Netherlands) Figure 3
Ultrasound images of a 2 day old premature infant born at 28 weeks scanned with a C8-5 ultrasound probe on 
a Philips iE33 ultrasound machine (Philips Medical Systems, Eindhoven, Netherlands). A: Sagittal scan presenting 
with bilateral grade III intraventricular haemorrhage, with blood in the caudo-thalamic groove (arrow). B: Coronal ultrasound 
scan presenting bilateral grade III intraventricular haemorrhage (arrows), with greater than 50% filling of the lateral ventricles. 
C: Coronal ultrasound scan with bilateral grade III post haemorrhagic hydrocephalus in the same infant six weeks later. The 
dilated anterior and temporal horns of the right lateral ventricle are apparent (arrows).Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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ence, neurodevelopmental disability or death in neonates
at risk for, or actually developing PHH. Two randomized
trials, both evaluating intraventricular streptokinase in 12
infants who developed PHVD were identified [50,51].
When intraventricular streptokinase was compared with
conservative management of PHVD, the numbers of
deaths and babies with shunt dependence were similar in
both groups. No information on the effect of intraven-
tricular streptokinase on disability is available. There is
cause for concern about meningitis and secondary IVH,
but numbers are insufficient to quantify the risks [50,51].
Overall, therefore, intraventricular fibrinolytic therapy
with streptokinase starting before one month of age in
infants developing PHVD is not recommended.
Ultrasound images of infants with different grades of intraventricular haemorrhage scanned with a C8-5 ultrasound probe on a  Philips iE33 ultrasound machine Figure 4
Ultrasound images of infants with different grades of intraventricular haemorrhage scanned with a C8-5 ultra-
sound probe on a Philips iE33 ultrasound machine. A: Coronal view of a 2 week old term infant with grade I intraven-
tricular haemorrhage highlighted in the left caudo-thalamic groove (arrow). B: Coronal view of a 1 day old premature infant 
born at 24 weeks with grade II intraventricular haemorrhage in the right caudo-thalamic groove (arrow) which fills less than 
50% of the ventricle. C: Coronal view of a 2 day old premature infant born at 24 weeks with a right grade IV intraventricular 
haemorrhage with hydrocephalus and extension into periventricular white matter (arrow).Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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Drainage, irrigation, and fibrinolytic therapy (DRIFT)
Recently, Whitelaw and colleagues [52] piloted a method
involving intraventricular administration of tissue plas-
minogen activator (tPA) and 72 hours drainage via two
ventricular catheters (one frontal on the right, and one
occipital on the left). The procedure, DRIFT (drainage,
irrigation, and fibrinolytic therapy) attempted to remove
intraventricular blood and the cytokines that are associ-
ated with hydrocephalus before it could become estab-
lished. They randomly assigned 70 preterm infants who
had gestational ages of 24 to 34 weeks with progressively
enlarging cerebral ventricles after IVH to two groups, (1)
drainage, irrigation, and fibrinolytic therapy to wash out
blood and cytokines and (2) tapping of CSF by reservoir
as required, to control excessive expansion and signs of
raised ICP (standard treatment). The results were that
DRIFT did not reduce VP shunt surgery or death in pre-
term infants with ventricular dilation after IVH when
compared with tapping of CSF to control excessive head
expansion or raised ICP. Tapping a ventricular reservoir
was relatively safe and effective in controlling hydroceph-
alus even in extremely small infants. Unfortunately, it was
concluded that secondary IVH is a factor that counteracts
any possible therapeutic effect from washing out old
blood. Therefore, the conclusion was that this innovative
intervention could not be recommended until more
objective evaluations can provide less equivocal findings.
Therefore, neither the DRIFT procedure nor acetazola-
mide and furosemide are effective in reducing the need for
shunting, and both forms of therapy have adverse effects.
It may be that the results to date of intraventricular fibri-
nolytic therapy have been negative because the treatment
(starting nearly two weeks after birth) had been adminis-
tered too late. Fibrosis, deposition of extracellular matrix
proteins and chronic inflammatory changes may already
have become irreversible. Furthermore, very low levels of
plasminogen and the presence of Plasminogen Activator
Inhibitor-1 (PAI-1) [53] would be expected to limit the
fibrinolytic effect of intraventricular streptokinase. As we
have alluded to, there is evidence that the cytokine, TGF-
beta plays a major role in the development of PHH.
Whitelaw et al. [13], further demonstrated that intraven-
tricular injection of tPA, on its own, increases the concen-
tration of TGF-beta in ventricular CSF. This could help to
explain the failure of intraventricular injection of fibrino-
lytic agents to prevent hydrocephalus. Thus, therapeutic
strategies need to continue to consider ways of removing,
blocking or preventing release of this and other cytokines
such as VEGF.
Preventative measures for IVH
As has been mentioned, approximately 80% of IVH
occurs by 72 h after birth but a considerable proportion of
IVH is visible on the first scan within a few hours [54].
This means that interventions to prevent IVH should ide-
ally be commenced prior to, or immediately after delivery.
Postnatal phenobarbital
The rationale for administration of postnatal phenobarbi-
tal to prevent IVH in low birth weight infants is under-
pinned by: a) the observation that phenobarbital may
dampen fluctuations in systemic blood pressure in prema-
ture infants [55], b) evidence that treatment with pheno-
barbital reduces the incidence of intracranial
haemorrhage in newborn beagles made hypertensive with
phenylephrine [56], c) experimental evidence that barbit-
urates can partially protect the brain against hypoxic-
ischaemic damage [57] and d) the suggestion that pheno-
barbital's free radical scavenging capacity may protect
after hypoxia-ischaemia [58]. However, the results of
three trials which used posthaemorrhagic ventricular dila-
tation or hydrocephalus as an outcome, reported no sig-
nificant difference between the control or treatment
groups [59-61]. The typical estimates from a meta-analysis
of these studies [25] provide little evidence of a reduction
in the risk of posthaemorrhagic ventricular dilatation
(typical relative risk 0.89, 95% CI 0.38, 2.08, typical risk
difference -0.01, 95% CI – 0.08, 0.06). Moreover, a large
double-blind randomised controlled trial by Kuban et al.
[62], found that in VLBW infants, phenobarbital was actu-
ally associated with an increased risk of developing any
subependymal-intraventricular-intraparenchymal haem-
orrhage. Although they did not use PHH as an independ-
ent outcome measure, this study complements our
assessment that the published evidence is very much
against postnatal phenobarbital preventing IVH. Further-
more, phenobarbital suppresses spontaneous breathing
in infants, causing a need for mechanical ventilation. In
spite of the lack of efficacy for this intervention, there is
still scope for researchers to consider perinatal interven-
tion with other modalities.
Surgical treatment other than shunt placement
As regards surgical treatment of PHH other than shunt
surgery, some authors have recommended ventricular
drains in preference to subgaleal reservoirs, due to the lev-
els of reported infection rates, but the numbers reported
are too small for any confidence [63]. The standard treat-
ment varies from centre to centre, and few have built up a
large series for analysis. The standard arms of the Ventricu-
lomegaly Trial [64] and the PHVD Drug Trial into aceta-
zolamide and furosemide [48] both used selective tapping
of CSF to control signs of raised ICP or excessive head
enlargement. Inserting a subcutaneous ventricular access
device (VAD), to facilitate repeated tapping of adequate
CSF volumes is widely practiced, without having been
tested by a randomised trial. All these measures are con-
sidered here.Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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Lumbar puncture and ventricular taps
Repeated early lumbar puncture (LP) or ventricular taps
have been advocated as a way of avoiding hydrocephalus
and protecting the brain from excess pressure. It was
thought that the risk of hydrocephalus and the need for a
VP shunt might be reduced by the removal of protein and
old blood from the CSF. In practice, the decision to
employ this strategy is taken from head circumference
changes, fontanelle examination, neurological signs, and
sequelae of raised ICP and from US measurement of ven-
tricular dilatation. In line with the Levene criteria for ven-
tricular indices [65], intervention usually occurs when the
ventricle reaches a diameter > 4 mm above the 97th per-
centile [66], although this is controversial as dilatation
may already be too great for subsequent taps to be effec-
tive and there have been reports of better outcomes with
taps performed before this cutoff [67]. A common practice
is to remove sufficient fluid to render the fontanelle soft
and depressed, typically in the region of 10 ml/kg/tap
[68]. This hypothesis has been tested in four randomised
trials involving premature infants in whom IVH (with or
without established enlargement) was diagnosed by US.
In total, four controlled trials, were identified, three being
randomised and the fourth using alternating allocation
[64,69-71]. Two trials evaluated repeated LPs in neonates
with IVH [70,71] and two trials evaluated repeated CSF
tapping in infants with IVH followed by progressive ven-
tricular dilatation [64,69]. The total number of infants in
the four studies was only 282, with 157 coming from the
Ventriculomegaly Trial. None of the trials found a signifi-
cant effect from CSF tapping on: a) need for shunt, b)
death, c) major disabilities in survivors, d) multiple disa-
bilities in survivors, or e) death or disability. Similarly, a
meta-analysis by Whitelaw of the results of all included
trials showed no significant effect of CSF tapping on any
of these outcomes [72]. Nevertheless, this does not take
into account the potential benefit of tapping to delay
shunt implantation until such time as the skin in VLBW
babies matures sufficiently to reduce the risk of shunt ero-
sion.
Repeated CSF tapping of preterm infants carries a theoret-
ical risk of introducing infection. None of the infants in
Dykes' 1989 study [69] developed CSF infection during
tapping but 11 of the 157 infants in the ventriculomegaly
trial developed CSF infections, all having had some CSF
taps (the infants in the control group were eventually
tapped if they developed symptoms or signs of raised ICP)
[64]. CSF infection (meningitis/ventriculitis) can be a seri-
ous adverse effect of early repeated CSF tapping. There is
no information about the frequency of needle-track
lesions from repeated ventricular taps, though anecdotal
evidence does exist. For example, a large (presumed trau-
matic) aneurysm of the pericallosal artery in an infant has
been observed after repeated ventricular taps by the senior
author (OS) (unpublished). Although it was a reasonable
hypothesis that early CSF tapping would reduce ICP and
remove protein and blood to clear the CSF pathways, the
meta-analysis by Whitelaw of the four controlled trials
failed to demonstrate any evidence of benefit [72]. More-
over, the secondary risk of infection and the discomfort of
the procedures were reiterated.
Assessment of the infants in the ventriculomegaly trial at
twelve months included an analysis in two groups: a)
infants who had a cerebral parenchymal lesion visible on
US at entry, and b) infants with no cerebral parenchymal
lesion at entry. In the group with parenchymal brain
lesions at entry, there was a difference in neurodevelop-
mental outcome at 12 months in favour of those who had
early CSF tapping [64]. This difference just achieved sig-
nificance at the 5% level, but caution was expressed in the
paper as to whether this finding could be due to chance.
The neurodevelopmental examination at 30 months in
the infants with parenchymal brain lesions at entry,
showed no difference between the two treatment groups.
Thus, this paper emphasised the importance of basing
clinical recommendations on consistent findings among
large groups of subjects.
Therefore, there is no evidence that early tapping of CSF
by LP or ventricular tap reduces the risk of poor neurode-
velopmental outcome, shunt dependence or death after
30 months follow up. The use of repeated taps was associ-
ated with an increased risk of central nervous system
infection. Thus, the use of early tapping is not a recom-
mended treatment modality, and removing CSF should
be reserved for cases where there is symptomatic raised
ICP, for example while temporising before more defini-
tive CSF diversion.
External ventricular drainage
After LPs prove to be unsuccessful, external ventricular
drainage (EVD) is often the next invasive step in the man-
agement of PHH. The catheter is typically inserted into the
dilated anterior horn of the right lateral ventricle under
sterile conditions. The end of the proximal catheter is sub-
cutaneously tunneled to a site on the scalp (or body) dis-
tant from the initial incision and connected to an
adjustable drainage system. EVD appears to be much
more effective than repeated LPs or ventricular taps in
evacuating sufficient volumes of CSF.
The infection rate with EVD ranges from unacceptable lev-
els [36] to very low rates reported by some authors,
despite long periods with an EVD [38,63]. One study by
Cornips et al. [63] reported no infections in 14 patients
with an EVD for PHH. They put this down to vigilant
monitoring and insertion of the EVD within the relatively
clean and stable environment of a neonatal ICU. StudiesCerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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by Berger et al. [73] and Rhodes et al. [74] each with 37
patients, reported infection rates of 5.4% and 6%, respec-
tively. Reinprecht et al. [38] studied 42 preterm patients
recording a 7.1% infection rate. Weninger et al. [75] cul-
tured CSF and/or the tip of the ventriculostomy catheter
in each of their 27 patients, reporting a 26% contamina-
tion rate but with no clinical or laboratory evidence of
ventriculitis. Importantly, these studies confirmed infec-
tion via CSF drainage catheters as an independent predic-
tor for poor neurodevelopmental outcomes [3].
Other problems such as over drainage and the develop-
ment of subdural hygromas can occur but may be mini-
mised by careful control of ICP. EVD also has the
advantage of allowing easy intrathecal administration of
drugs. The effect of EVD on shunt dependency and neuro-
logical outcome is at present not actually known. Long
standing EVD may encourage the need for subsequent
shunt insertion by decreasing natural CSF reabsorption.
On the other hand, the need for permanent shunting may
be reduced by the continuous removal of bloody and pro-
tein rich CSF. Nevertheless, the rate of permanent shunt-
ing after EVD is 64–68% [63,74].
Subgaleal shunts
Ventriculo-subgaleal shunts have been recommended as a
more physiological and less invasive means of achieving
CSF diversion until VLBW infants gain adequate weight,
and the blood and protein levels in CSF are low enough,
before a permanent shunt can be placed. In one study of
this procedure to evaluate the effectiveness and complica-
tions over a 1-year period [76], the ventriculo-subgaleal
shunt controlled the progression of hydrocephalus in all
6 premature infants, as assessed by clinical and imaging
parameters, and a permanent shunt was avoided in 1
patient (16.6%). However, 4 patients developed shunt
infections, 1 involved the ventriculo-subgaleal shunt
itself, and 3 occurred immediately after conversion to VP
shunt. The total infection rate in these cases was two
thirds, though there was only a 1% shunt infection rate for
primary implantation in their institution at that time.
Therefore, according to this study, placement of ven-
triculo-subgaleal shunts for interim CSF diversion in
neonates with posthaemorrhagic hydrocephalus is effec-
tive as a temporary method of CSF diversion. However, it
is associated with a worryingly high CSF infection rate.
This study suffers from a small sample size in an under-
studied area, and thus cannot yet be treated as a standard
therapeutic option, though it seems worthy of further
study.
A potential cause for infection in this study may have been
CSF stasis just beneath the extremely thin skin of the pre-
mature infants, promoting colonisation by skin flora, as
all the infections were staphylococcal. It is postulated that
CSF sampling before conversion to a permanent shunt
and replacement of the proximal hardware, which may
have been in situ for a prolonged period, may decrease the
infection rates. However, until this is researched further, it
cannot be a recommended treatment.
Subcutaneous reservoir
The subcutaneous reservoir or VAD is another frequently
used option in the management of PHH. This avoids
repeated needle tracks through the brain and potential
injury. Reservoirs are tapped up to three times a day and
the amount of CSF removed can be adjusted to the open-
ing pressure. An important drawback of VADs (and LPs) is
that the removal of CSF is intermittent. The fluid buildup
and resulting rise of ICP between taps might be detrimen-
tal. The major complications of VADs are ventriculitis,
shunt infection, skin necrosis, CSF fistula, or subdural
hygroma.
One recent study found hyponatraemia to be a conse-
quence of serial CSF punctures in preterm infants with a
Rickham VAD [77]. This has also been found in studies
performed less recently [78], and has also been reported
as a consequence of EVDs [63]. However, hyponatraemia
as a consequence of CSF tapping or drainage is totally pre-
dictable and preventable, and can easily be treated with
diligent monitoring and replacement [77,78]. The rates of
infection in VADs reported in the literature are actually
very low. However, among patients who received a subcu-
taneous reservoir, subsequent shunting was necessary in
75–88% [79-81].
On balance, therefore, the current evidence for VAD use is
conflicting. A study by Hudgins et al. [80] in 149 infants
with PHH recorded an 8% infection rate and concluded
that the device can be recommended for several months
with acceptable rates of infection, blockage and wound
complications. On the other hand, a study by Richard et
al. [82] into 64 infants recorded a 22% infection rate and
did not suggest an Ommaya reservoir was beneficial in
terms of mortality, prevention of shunt placement or neu-
rological outcome. Nevertheless, a contemporary study by
Brouwer  et al. [83] assessed two separate groups, 26
infants admitted during 1992–7 and 50 admitted during
1998–2003, treated with a ventricular reservoir. Their
results suggest a learning curve reflecting the benefits of
experience, whereby significantly fewer complications
were recorded in the second period. It is also important to
emphasise that the repeated punctures need to be under-
taken with meticulous aseptic technique in order to min-
imise introduction of organisms from the skin. They
suggest that in experienced hands, a ventricular reservoir
is a safe treatment to ensure adequate removal of CSF in
preterm infants with PHH.Cerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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Ommaya reservoir followed by shunt or ETV
A 2007 study has taken this a step further and evaluated
treating PHH with an Ommaya reservoir, followed by VP
shunt and/or endoscopic third ventriculostomy (ETV)
[84]. There were 18 premature babies affected by IVH
grades II to IV implanted with a reservoir. CSF was inter-
mittently aspirated percutaneously from the VAD accord-
ing to clinical requirements and ultrasonographic follow-
up. Fourteen of the patients suffered progressive ventricu-
lar dilatation and underwent VP shunt implantation (5
patients) or ETV (9 infants). One of the infants died dur-
ing the study, and at the end of the follow-up period, 10
out of 17 premature neonates affected by PHH were shunt
free (59%). They concluded that the combination of
Ommaya reservoir, VP shunt, and the aggressive use of
ETV, as either a primary treatment or as an alternative to
shunt revision, allowed for a significant reduction of
shunt dependency in a traditionally shunt-dependent
population. Therefore, this is a promising approach,
deserving of further study.
Improvements in antenatal and perinatal care
A general decrease in IVH has been noted in developed
countries over the last 10 years despite an increase in sur-
vival of very immature infants. This may in fact be due to
dedicated neonatal teams who are becoming experienced
at handling premature babies.
Maternal corticosteroid administration before preterm
delivery has been mainly responsible for this decrease in
IVH as demonstrated in a 2006 Cochrane review [85].
Indeed, in a meta-analysis of previously published trials,
antenatal corticosteroids have been confirmed to reduce
the incidence of IVH in premature children. The com-
bined odds ratio for the development of IVH was 0.38
when comparing antenatal corticosteroids with placebo
[86]. A promising randomised control trial by Liu et al.
[87] evaluated whether combined antenatal corticoster-
oid and vitamin K administration has a benefit, over and
above that of corticosteroid or vitamin K used alone, in
reducing the frequency and the degree of periventricular-
intraventricular haemorrhage (PIVH) in premature new-
borns of less than 35 weeks' gestation. More infants in the
control group had grades III or IV intracranial haemor-
rhage after birth (p = 0.049). After antenatal supplement
of dexamethasone and vitamin K1, both the total inci-
dence of PIVH and the frequency of severe PIVH decreased
significantly. Thus, many of the advances for treating PHH
may be pre-emptive and the focus for research into
improving antenatal care and interdisciplinary
approaches is encouraging.
Of the other pharmacological interventions assessed,
antenatal indomethacin appeared promising. However,
results of a multicentre trial by Pringle et al. [88] of
indomethacin in 1200 infants with birth weights < 1100
g showed that the reduction in IVH was not accompanied
by an improvement in survival without disability, and a
similar trial from Dani et al. [89] showed ibuprofen to be
ineffective in preventing IVH. Nevertheless, although the
long-term benefits are unproven, the therapeutic value of
indomethacin in reducing the incidence of IVH, and
hence PHH, should be noted [90]. It has been demon-
strated in multiple single-centre studies to decrease the
incidence of IVH in VLBW preterm infants [91,92] and,
therefore, presumably, improves long term outcome. Fur-
thermore, initial studies of neuromuscular paralysis with
ventilation seemed to have a favourable effect on inci-
dence and severity of IVH, but there is still uncertainty
regarding its long term pulmonary and neurological
effects [93]. Evidently, stronger evidence is required
before this can be recommended.
Future surgical trends for PHH might include contribu-
tions from the fields of robotics, image-guided neuroen-
doscopy, 'in utero' therapies and the applications of stem
cell research, though these remain speculative [94].
Implications for practice
On the basis of available evidence, routine use of early
CSF tapping for infants at risk of, or actually developing
PHH cannot be recommended. It would seem wise to be
conservative in the management of infants developing
PHH to reduce the risk of iatrogenic damage. Routine
scanning is important to determine the presence or
absence of parenchymal brain lesions, as they affect prog-
nosis. The infant should be followed with repeated meas-
urements of head circumference and ventricular width, as
well as clinical examination of neurological status and
fontanelle tension. Despite the lack of evidence from ran-
domised trials, CSF drainage is obviously important if
there is symptomatic raised ICP, as shown by either a
deterioration in neurological signs with a tense fontanelle
[72], or directly measured CSF pressure > 12 mm Hg [72].
Some evidence supports CSF drainage also in the presence
of either decreasing diastolic velocities on cerebral artery
Doppler waveforms [68] or deteriorating sensory evoked
potentials [72]. However, neither of the latter can be
regarded as routine clinical tools, so require further evalu-
ation before contemplating adding to the routine criteria
for draining CSF.
Many infants need few, if any CSF taps but continue to
expand their ventricles and heads at a rate that is clearly
above normal. If this excessive expansion continues until
the clots have largely absorbed, shunt surgery should be
considered. The surgeon may wish to postpone surgery if
the infant is still extremely small, particularly if skin qual-
ity is poor, if there is infection, or if the CSF still has visible
blood or high protein. If it has been necessary to tap theCerebrospinal Fluid Research 2009, 6:1 http://www.cerebrospinalfluidresearch.com/content/6/1/1
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CSF repeatedly, then the case for earlier shunt surgery is
stronger, because repeated CSF taps, particularly ventricu-
lar taps, create morbidity.
Conclusion
Neither treatment by repeated lumbar or ventricular tap-
ping, nor the use of acetazolamide and furosemide to
reduce CSF production, are proven to prevent the need for
shunt surgery or improve neurodevelopmental outcomes.
Additionally, both have appreciable adverse effects. Phase
1 clinical trials of intraventricular fibrinolytic therapy and
a small randomised trial have not given encouraging
results. There is insufficient evidence for postnatal pheno-
barbital in preventing IVH, and drainage, irrigation, and
fibrinolytic therapy to wash out blood and cytokines is
both highly invasive, experimental and showed no bene-
fit, so cannot be recommended routinely. However, it
may be that earlier use of an implanted reservoir for tap-
ping could improve outcomes. Overall, therefore,
although the proportion of premature infants suffering
IVH has declined, PHH is still a serious complication for
which we do not have a definitive treatment. Research
clearly needs to focus more on the mechanisms of hydro-
cephalus and radically new therapeutic approaches will
have to be considered. In the interim, advances in paedi-
atric intensive care and neonatal medicine offer hope in
preventing PHH.
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